Xalkori
Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients
At five years, 60 percent of patients receiving first-line Lorbrena were alive without progression, according to Phase III data reported at ASCO.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
Xcovery Holdings Seeking FDA Approval for Frontline Ensartinib in ALK-Positive NSCLC
The firm filed a new drug application with the FDA for its ALK inhibitor ensartinib, which is already approved for advanced ALK-positive NSCLC in China.
Pfizer Reports Mixed Revenues for Oncology Products in Q4, Looks to Advancing Pipeline in 2024
Premium
With the completion of its acquisition of Seagen in December, the firm is aiming to become a leader in precision oncology.
FDA Approves BMS's Augtyro for Advanced ROS1-Positive NSCLC
The approval is based on results from the Phase I/II TRIDENT-1 clinical trial of Augtyro in both TKI-pretreated and TKI-naïve ROS1-positive NSCLC.